Regulatory Freeze Under the New Trump Administration: Implications for DSCSA Compliance

January 22, 2025 Christian Souza Leave a comment

The Drug Supply Chain Security Act (DSCSA) compliance deadlines are fast approaching. Despite the political landscape’s recent shifts, these deadlines remain firmly in place. The regulatory freeze introduced by the Trump administration in January 2025 has generated discussions, but it does not alter these legally mandated timelines. Businesses must continue their preparations to ensure compliance.

What Does the Regulatory Freeze Mean?

The regulatory freeze halts federal agencies from introducing new rules or enforcing pending regulations. While this may delay updates or further guidance from the FDA, the DSCSA deadlines remain unaffected. Congress established these timelines, making them non-negotiable and critical for ensuring a safer pharmaceutical supply chain.

It is important to note that the FDA has previously extended certain enforcement dates to allow companies more time to prepare. With these extended dates now firm, proactive preparation is more critical than ever.

Serialization and Track-and-Trace: Cornerstones of Compliance

Serialization and track-and-trace systems are fundamental for meeting DSCSA requirements. Serialization uniquely identifies drug packages by providing details such as product code, serial number, lot number, and expiration date. These systems enhance transparency across the supply chain by enabling:

Electronic data exchange.

Product tracking at every stage.

Verification of product authenticity.

Serialization not only ensures compliance with DSCSA but also plays a vital role in preventing counterfeiting, streamlining recalls, and bolstering patient safety. Integration of serialization and data exchange systems into your operations is a necessary step toward achieving compliance.

Preparing for DSCSA Compliance: Key Deadlines

Under the DSCSA, different segments of the pharmaceutical supply chain face specific deadlines: Manufacturers and repackagers: May 27, 2025

Wholesale distributors: August 27, 2025

Larger dispensers: November 27, 2025

These dates represent milestones in the journey toward a safer and more transparent supply chain. For manufacturers and repackagers, compliance preparations should already be in advanced stages, as their deadline is just a few months away.

The Final Stretch: Building Trust and Excellence

The DSCSA deadlines are more than just administrative requirements; they represent a pivotal opportunity for the pharmaceutical industry to enhance patient safety and strengthen supply chain integrity. Missing these deadlines can disrupt operations and damage trust in a highly regulated industry. Acting now not only ensures compliance but also establishes your organization as a leader in transparency, safety, and reliability—delivering long-term value to patients and partners.

Looking Ahead

Ensuring compliance with DSCSA is not just about meeting deadlines; it’s about setting a standard for excellence in the pharmaceutical supply chain. Proactive preparation, robust systems, and adherence to serialization requirements will not only secure compliance but also reinforce your company’s role as a trusted industry leader.

Deadlines, DSCSA

Countdown to May 27th: Manufacturers & Repackagers Prepare for DSCSA

January 14, 2025 Christian Souza Leave a comment

The clock is ticking for pharmaceutical manufacturers and repackagers. By May 27, 2025, they must comply with the Drug Supply Chain Security Act (DSCSA) requirements, a crucial step toward achieving transparency, safety, and accountability within the U.S. drug supply chain. This deadline marks a critical step in creating an interoperable electronic system to track and trace prescription drugs throughout their lifecycle. For those in the pharmaceutical supply chain, the time to act is now.

Why May 27, 2025, Matters

This DSCSA deadline specifically targets manufacturers and repackagers, mandating compliance with enhanced product tracing and verification systems. By this date, every prescription drug must have a standardized serialized identifier encoded in a 2D Data Matrix barcode. Additionally, manufacturers and repackagers must ensure that their systems can provide transaction information (TI), transaction history (TH), and transaction statements (TS) in electronic formats.

Failure to comply could result in regulatory penalties, loss of market access, and reputational damage. Beyond legal ramifications, non-compliance undermines the collective industry goal of ensuring a safer supply chain for patients and consumers.

Countdown to May 27th: Manufacturers & Repackagers Prepare for DSCSA — RX Manufacturers: Be ready for the DSCSA May 27, 2025 deadline

Key Requirements to Meet Before the Deadline

Serialization Compliance Manufacturers and repackagers must ensure that every unit-level package of prescription drugs includes a unique product identifier, expiration date, lot number, and serial number. These identifiers play a critical role in preventing counterfeit drugs from entering the supply chain.
Data Interoperability The DSCSA requires interoperable systems for sharing transaction information. Manufacturers and repackagers must adopt solutions that integrate seamlessly with partners across the supply chain to enable efficient and secure data exchange.
Verification Systems Companies must have systems in place to verify the authenticity of serialized identifiers. This includes the ability to respond promptly to verification requests and investigate any suspect products.
Record Retention Retaining accurate transaction records for a minimum of six years is mandatory. These records must be readily accessible to support investigations and audits.

Challenges on the Road to Compliance

While the DSCSA represents a significant step forward for the pharmaceutical industry, achieving compliance is not without its hurdles:

Technological Integration: Many companies face challenges in integrating serialization and traceability systems with their existing ERP or supply chain platforms.

Data Accuracy: Ensuring the accuracy and integrity of shared data requires rigorous testing and quality assurance.

Collaboration: Manufacturers and repackagers must work closely with trading partners to align their systems and processes for seamless compliance.

Time Constraints: With the deadline fast approaching, companies must act swiftly to address gaps in their compliance strategies.

Steps to Accelerate Compliance

Audit Current Systems Conduct a thorough review of your existing systems to identify gaps in serialization, data exchange, and verification capabilities.
Invest in Scalable Solutions Choose DSCSA-compliant solutions that integrate easily with your supply chain operations. Scalable platforms ensure long-term adaptability as requirements evolve.
Collaborate with Trading Partners Open communication with wholesalers, distributors, and dispensers is critical. Ensure alignment on data formats, protocols, and system interoperability.
Train Your Teams Equip your staff with the knowledge and skills to operate and troubleshoot new systems effectively. Training programs should cover serialization processes, regulatory updates, and verification procedures.
Engage DSCSA Experts Partnering with industry specialists can provide invaluable guidance. Experts can help streamline your compliance efforts, reduce risks, and ensure readiness ahead of the deadline.

The Benefits of Proactive Compliance

Meeting the DSCSA requirements is not merely about avoiding penalties. Compliance enhances operational efficiency, bolsters supply chain security, and fosters trust among trading partners and consumers. By investing in compliance today, manufacturers and repackagers position themselves as leaders in delivering safe and reliable medications.

Don’t Wait – Start Now

The May 27, 2025, DSCSA deadline is non-negotiable, and the window for preparation is closing. Manufacturers and repackagers must take decisive action to meet the stringent requirements. By prioritizing serialization, interoperability, and collaboration, the pharmaceutical industry can achieve a safer and more transparent supply chain—one that protects patients and upholds public trust.

If your organization is still navigating the path to compliance, it’s time to act. Solutions tailored for the pharmaceutical industry can help you achieve your goals swiftly and effectively. Prepare now to ensure a seamless transition and secure your place in a compliant, forward-looking supply chain.

DSCSA, Uncategorized

DSCSA Exemptions: What You Need to Know for Compliance

October 21, 2024 Christian Souza Leave a comment

The Drug Supply Chain Security Act (DSCSA) is designed to enhance the safety and traceability of pharmaceutical products. Recent FDA guidance, issued on October 9, 2024, introduced temporary exemptions from certain DSCSA requirements, offering businesses more time to comply. DSCSA Exemptions: What You Need to Know for Compliance is essential for understanding these exemptions’ implications and ensuring companies take the necessary steps to remain on track with compliance efforts.

The Significance of DSCSA Exemptions

The DSCSA mandates the use of Electronic Product Code Information Services (EPCIS) to ensure accurate and secure transaction data exchange across the pharmaceutical supply chain. Many businesses, however, have struggled to implement these systems due to technological challenges or data issues. In response, the FDA has offered temporary exemptions to give companies more time to refine their systems and work toward full compliance.

Although these exemptions can ease immediate pressure, businesses must recognize that the FDA continues to closely monitor compliance progress. Companies failing to show significant progress could still face penalties, even if they qualify for exemptions. A partially functioning system is better than none—delaying efforts could expose your organization to serious risks.

Key Dates and Eligibility for Exemptions

The FDA exemptions apply to businesses actively working toward DSCSA compliance, specifically those who have already made strides in establishing electronic data connections by November 27, 2024. The exemption timelines for various sectors are as follows:

Manufacturers and Repackagers: Exempt until May 27, 2025
Wholesale Distributors: Exempt until August 27, 2025
Dispensers (26+ employees): Exempt until November 27, 2025
Small Dispensers (<26 employees): Exempt until November 27, 2026

No formal notification to the FDA is required to take advantage of these exemptions, but businesses are expected to use the time to finalize compliance preparations.

Why Immediate Action Remains Crucial

Despite these exemptions, waiting until the last minute to establish DSCSA compliance systems is a risky approach. Regulatory authorities will continue to assess progress, and the extended timelines shouldn’t be seen as an excuse for inaction.

Beyond regulatory concerns, failing to implement DSCSA solutions could impact key business relationships. Major trading partners like AmerisourceBergen, McKesson, and Cardinal Health require that compliance data be transmitted electronically through EPCIS.

Image to represent: Drug Supply Chain Security Act (DSCSA) is designed to enhance the safety and traceability of pharmaceutical products

Developing Strong SOPs for Compliance

In addition to implementing technology for compliance, businesses need to have clearly defined Standard Operating Procedures (SOPs) for managing DSCSA requirements. During an audit, one of the first things an auditor will request is your SOP. Not having one in place could significantly increase your compliance risks.

Your SOP should outline how your company handles serialized data, transaction verification, and real-time data exchanges. Ensuring that your SOP is comprehensive and audit-ready is key to avoiding compliance issues in the future.

What Does This Mean for Different Sectors?

The FDA’s exemptions give businesses additional time, but companies in all sectors must continue working toward full compliance to avoid negative consequences. Here’s how the exemptions impact various types of organizations:

Pharmacies and Dispensers: The extra time allows you to stabilize your systems, but ensuring proper serialized data exchange is essential to maintain business relationships with suppliers and customers.
Manufacturers and Wholesalers: If your electronic systems are still under development, the exemption period allows you to refine them. However, failing to meet compliance could result in the loss of major trading partners.

Steps to Ensure DSCSA Compliance

With enforcement deadlines fast approaching, here are some critical actions businesses should take to ensure they meet DSCSA requirements:

Audit Current Systems: Evaluate your existing systems to determine whether they are capable of handling serialized data exchanges.
Upgrade Technology: If your current system is outdated or not equipped to manage real-time EPCIS data exchange, consider upgrading it now to avoid penalties.
Ensure Data Accuracy: Setting up the infrastructure is only the first step. Make sure that the serialized data you’re exchanging with trading partners is accurate and reliable.
Train Your Staff: Your employees need to understand how to manage serialized data exchanges and work with your DSCSA compliance solution effectively.
Develop or Update Your SOP: If you don’t already have a clear SOP in place, now is the time to create one. A well-documented SOP will not only help you meet regulatory requirements but also streamline your operations.
Monitor Your Trading Partners’ Compliance: Be proactive in ensuring that your trading partners are also compliant. This will help avoid potential disruptions in your supply chain.

Final Thoughts

The FDA’s temporary exemptions offer a brief respite, but achieving full DSCSA compliance is essential for protecting your business from regulatory penalties and operational setbacks. It’s not just about meeting legal requirements—compliance also plays a crucial role in maintaining strong business relationships and ensuring the smooth operation of your supply chain.

By acting now and ensuring that both your technology and procedures are up to standard, your business can avoid the risks associated with non-compliance and continue to thrive in a tightly regulated industry.

DSCSA

FDA’s Firm Stance on DSCSA Compliance: No More Delays

June 6, 2024 Christian Souza

The FDA recently emphasized the urgent need for compliance with the Drug Supply Chain Security Act (DSCSA), impacting the pharmaceutical industry significantly. At the 2024 FDLI Annual Conference, Patrizia Cavazzoni, Director of the FDA’s Center for Drug Evaluation and Research (CDER), confirmed that there will be no further extensions to the compliance deadline. This announcement marks a critical step in the FDA’s ongoing efforts to secure the pharmaceutical supply chain.

Continue reading →

DSCSA, FDA

FDA Official Will not extend the 2023 deadline

August 18, 2021 Christian Souza

Deadline will not be extended

As reported by the Regulatory Focus, the FDA will not delay the interoperability deadline for the DSCSA 2023 deadline. You can for sure group the saleable returns requirements as well. The US Food and Drug Administration is working “full tilt” towards implementing requirements calling for manufacturers and trading partners to have a full interoperable electronic track and trace system in place by 2023.

Continue reading →

DSCSA, FDA

The FDA’s New Guidance for 2021 Explained

August 10, 2021 Christian Souza

As the premier regulatory body for ingestible products in the United States, the FDA (Food and Drug Administration) is responsible for safeguarding public health through safety measures, guidance, and regulations. The importance of the FDA’s job cannot be stressed enough, and in the current global health crisis we find ourselves in, this responsibility is even more critical.

The FDA’s annual guidance schedule is often more aspirational than strictly practical, but it does a good job in providing useful insights into what areas the FDA’s CDER (Center for Drug Evaluation and Research) has given priority for that particular year.

You can find updated lists for the FDA’s guidance for 2021 here. In this article, we’ll focus on the guidance as it relates to the DSCSA (Drug Supply Chain Security Act).

Continue reading →

FDA, FSMA

FDA’s Food Safety Modernization Act (FSMA), Explained

May 24, 2021 Christian Souza

One of the most important things for a country to safeguard is the health and safety of its residents. Hazards don’t always arrive in plain sight and are most often hidden in things we trust and consume on a daily basis. The biggest example of this is the food we eat.

Food has the ability to nourish us and provide us with the energy to thrive in our existence, but it can also severely damage our health if not mandated properly. This is the main reason why the FDA’s Food Safety Modernization Act (FSMA) was enacted in 2011 by President Obama.

The specifics of the act are complicated, and the nature of the subject matter requires extensive regulations to be upheld. In this article, we’ll give you an overview of everything worth knowing about the FSMA guidelines. We’ll show you the importance of food regulation standards, we’ll get into each aspect of the FSMA in more detail and we’ll end with what’s changed for 2021.

Continue reading →

DSCSA, HDA, PDG

2 Organizations You Need to Join to Get Ready for the DSCSA Phase II

April 19, 2021 Christian Souza

If you are a pharmaceutical company serious about meeting the requirements of Phase II of the DSCSA, there are two organizations you must join.

The first is the Partnership for DSCSA Governance, or the PDG. It is an organization formed by manufacturers, wholesalers, dispensers, and solution providers that are working to solve the interoperability requirements for the DSCSA for 2023. The PDG is a 501(c)(6) nonprofit business association requiring a yearly membership fee to join.

The other is the Healthcare Distribution Alliance, or HDA, which is a long-running organization that represents many members of the pharma supply chain in a quest to advocate for public policy that supports patient access to medical products through safe, efficient, and effective distribution. The HDA also requires a yearly membership fee.

Today’s post will look at both organizations, profile what they do, and then let you know why joining them is crucial for getting the most out of the DSCSA.

Continue reading →

…a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance